The use of active mechanical circulatory support is growing rapidly around the world. The hope is that these systems will improve survival after the most severe form of acute heart failure, cardiogenic shock. A recent clinical trial has shown that extracorporeal life support (ECLS) does not reduce 30-day mortality after cardiogenic shock. The finding is likely to influence future guidelines.
